LTRN — Lantern Pharma Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1763950 ·
Last close
$0.37
Market Cap
$4.67M
52W High
$4.34
52W Low
$0.36
ADV30
247,541
Next earnings
2026-11-17

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,377,883 696,615 8,524,529 7,615,813 7,114,276
Jun 2026 0 — -3,508,090 -7,072,124 8,602,349 6,660,170 11,819,601
Mar 2026 0 — -3,405,247 -3,329,171 7,223,067 4,917,796 3,777,366
Dec 2025 0 — -4,202,762 -4,074,217 11,035,811 4,422,838 4,501,587

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,077,633
Investing CF
$9,166,834
Financing CF
$1,498,240
CapEx
$-1,715
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.66
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-103,546,350
Inventory
—
Receivables
—
ST Investments
$701,085
EBIT TTM
$-15,465,899
Pretax Income TTM
$-18,652,935
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -17,978,494 -17,119,438 11,035,811 4,501,587 6,534,224 -15,676,980
Dec 2024 0 -22,216,437 -20,781,213 25,571,792 4,384,018 21,187,774 -17,813,201
Dec 2023 0 -17,877,570 -15,961,534 43,647,616 2,739,682 40,907,934 -14,346,548
Dec 2022 0 -14,432,753 -14,259,946 58,836,321 2,798,297 56,038,024 -12,767,492

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-18,652,935
OpCashFlow TTM
—
Assets (Latest)
$8,602,349
Forward EPS
$-2.02

Peers — same industry

TickerNameMarket CapLastDaily %
CNSY CERENOME, INC. $4.78M $0.63 —
PCSA Processa Pharmaceuticals, Inc. $4.84M $1.73 —
ADXN Addex Therapeutics Ltd. $4.43M $3.50 —
SKYE Skye Bioscience, Inc. $4.43M $1.00 —
CDT CDT Equity Inc. $4.93M $0.36 —

News headlines (Yahoo Finance, 1h cache)

Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-18 13:00 · Yahoo
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
2026-10-08 12:00 · Yahoo
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
2026-10-08 11:05 · Yahoo
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
2026-10-07 12:31 · Yahoo
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
2026-09-30 20:01 · Yahoo
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
2026-09-23 11:45 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
2026-09-17 12:20 · Yahoo
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
2026-09-05 14:50 · Yahoo
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
2026-08-21 12:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.